Amphastar Pharmaceuticals - AMPH Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AMPH shares.
View AMPH analyst ratings or view top-rated stocks.

3 brokerages have issued twelve-month target prices for Amphastar Pharmaceuticals' stock. Their AMPH share price forecasts range from $32.00 to $44.00. On average, they predict the company's stock price to reach $38.50 in the next year. This suggests a possible upside of 36.2% from the stock's current price.
View analysts price targets for AMPH or view top-rated stocks among Wall Street analysts.

Amphastar Pharmaceuticals' stock was trading at $23.29 on January 1st, 2022. Since then, AMPH shares have increased by 21.4% and is now trading at $28.27.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our AMPH earnings forecast.

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) released its earnings results on Monday, August, 8th. The company reported $0.33 earnings per share for the quarter, beating analysts' consensus estimates of $0.30 by $0.03. The firm had revenue of $123.47 million for the quarter, compared to analyst estimates of $118.17 million. Amphastar Pharmaceuticals had a trailing twelve-month return on equity of 18.51% and a net margin of 19.06%. During the same quarter in the prior year, the business posted $0.21 earnings per share.

35 employees have rated Amphastar Pharmaceuticals Chief Executive Officer Jack Y. Zhang on Glassdoor.com. Jack Y. Zhang has an approval rating of 35% among the company's employees. This puts Jack Y. Zhang in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 48.0% of employees surveyed would recommend working at Amphastar Pharmaceuticals to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amphastar Pharmaceuticals investors own include Cara Therapeutics (CARA), Gilead Sciences (GILD), Amicus Therapeutics (FOLD), Exelixis (EXEL), CNX Resources (CNX), Immunomedics (IMMU), AbbVie (ABBV), Cellectis (CLLS), Clovis Oncology (CLVS) and Galectin Therapeutics (GALT).

Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH."

Amphastar Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Federated Hermes Inc. (6.70%), State Street Corp (3.14%), Nantahala Capital Management LLC (0.00%), Caption Management LLC (0.00%), Assenagon Asset Management S.A. (0.86%) and Northern Trust Corp (0.85%). Insiders that own company stock include David Maris, Diane G Gerst, Floyd F Petersen, Howard Lee, Jack Y Zhang, Jason B Shandell, Michael A Zasloff, Richard K Prins, Richard Koo, Rong Zhou, William J Peters, William J Peters and Yakob Liawatidewi.
View institutional ownership trends.

Shares of AMPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AMPH stock can currently be purchased for approximately $28.27.

Amphastar Pharmaceuticals (NASDAQ:AMPH) has a market capitalization of $1.39 billion and generates $437.77 million in revenue each year. The company earns $62.12 million in net income (profit) each year or $1.78 on an earnings per share basis.

The company employs 1,761 workers across the globe.

Amphastar Pharmaceuticals' mailing address is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. The official website for the company is www.amphastar.com. The company can be reached via phone at (909) 980-9484, via email at jasons@amphastar.com, or via fax at 909-980-8296.